2004. Point mutations in domain V of the 23S rRNA gene are the primary cause of clarithromycin resistance in clinical Helicobacter pylori isolates in the United States
Session: Poster Abstract Session: Antimicrobial Resistance Mechanisms
Saturday, October 29, 2016
Room: Poster Hall
  • 161019 FINAL IDWeek Poster - H pylori 4x6.pdf (659.4 kB)
  • Background: Resistance to clarithromycin in H. pylori has been reported in several countries to be caused by specific point mutations in the 23S rRNA gene, particularly at positions 2143 and 2142 of domain V. Studies comparing these mutations in United States clinical isolates to antimicrobial susceptibility results determined using the gold standard agar dilution method are lacking. The purpose of this study was to assess for these point mutations in clinical H. pylori isolates in the United States, and to determine their ability to predict phenotypic antimicrobial susceptibility.

    Methods: Archived H. pylori isolates previously submitted to the clinical microbiology laboratory at Mayo Clinic for antimicrobial susceptibility testing (AST) were retrieved. AST had been performed by agar dilution according to CLSI guidelines. The isolates were thawed, cultured on Columbia agar under microaerophilic conditions at 35°C, and then lysed using bead beating. A 150 bp segment of the 23S rRNA gene was amplified via polymerase chain reaction and subsequently bidirectionally sequenced using dye-terminator technology. The presence of mutations at the 2143 and/or 2142 positions was recorded and compared to prior AST results.

    Results: A total of 118 H. pylori isolates were tested. 7 isolates yielded insufficient H. pylori DNA for sequencing or did not have prior clarithromycin AST performed and were excluded from further analysis. For the remaining 111 isolates, there was concordance between phenotypic AST and genotypic results in 106 (95%) isolates. Of these, 21 (20%) were susceptible to clarithromycin and 85 (80%) were resistant. An A2143G mutation was identified in 70 (82%) isolates, A2142G in 12 (14%), and A2142C in 3 (4%). There was discordance between AST and genotype in 5 (5%) isolates; 3 had a resistant phenotype but a wild-type sequence, and 2 had a susceptible phenotype but an A2143G mutation.

    Conclusion: 23S rRNA gene mutations predict phenotypic resistance to clarithromycin in clinical H. pylori isolates. Resistance was most commonly conferred by A2143G, followed by A2142G and A2142C point mutations. The prevalence of each mutation in the United States is similar to that reported from other parts of the world.

    Derrick Chen, MD1, Scott Cunningham, MT(ASCP), MS2, Nicolynn Cole, MT(ASCP)1, Peggy Kohner, MT(ASCP)1 and Robin Patel, MD, FIDSA, D(ABMM)3, (1)Division of Clinical Microbiology, Mayo Clinic, Rochester, MN, (2)Division of Clinical Microbiology, Dept. of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, (3)Divisions of Clinical Microbiology and Infectious Diseases, Mayo Clinic, Rochester, MN


    D. Chen, None

    S. Cunningham, None

    N. Cole, None

    P. Kohner, None

    R. Patel, Roche: Consultant , Travel reimbursement
    TIB: Patent Holder , Licensing agreement or royalty
    IDSA: Editor , Travel reimbursement and editor's stipend

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.